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Abstract: In protein engineering and synthetic biology, Methanosarcina mazei pyrrolysyl-tRNA
synthetase (MmPylRS), with its cognate tRNAPyl, is one of the most popular tools for site-specific
incorporation of non-canonical amino acids (ncAAs). Numerous orthogonal pairs based on engineered
MmPylRS variants have been developed during the last decade, enabling a substantial genetic code
expansion, mainly with aliphatic pyrrolysine analogs. However, comparatively less progress has been
made to expand the substrate range of MmPylRS towards aromatic amino acid residues. Therefore,
we set to further expand the substrate scope of orthogonal translation by a semi-rational approach;
redesigning the MmPylRS efficiency. Based on the randomization of residues from the binding pocket
and tRNA binding domain, we identify three positions (V401, W417 and S193) crucial for ncAA
specificity and enzyme activity. Their systematic mutagenesis enabled us to generate MmPylRS
variants dedicated to tryptophan (such as β-(1-Azulenyl)-l-alanine or 1-methyl-l-tryptophan) and
tyrosine (mainly halogenated) analogs. Moreover, our strategy also significantly improves the
orthogonal translation efficiency with the previously activated analog 3-benzothienyl-l-alanine.
Our study revealed the engineering of both first shell and distant residues to modify substrate
specificity as an important strategy to further expand our ability to discover and recruit new ncAAs
for orthogonal translation
Keywords: aromatic amino acid analogs; site-specific incorporation; genetic code expansion;
Methanosarcina mazei pyrrolysyl-tRNA synthetase (MmPylRS); non-canonical amino acids (ncAAs);
orthogonal pairs; ribosomal translation
1. Introduction
Protein translation is a process by which a protein sequence is being built up according to the
information provided in the messenger RNA. In nature, there is a limited set of canonical amino
acids (cAAs) that can be utilized as building blocks in this process. Conversely, non-canonical
amino acids (ncAAs) can be incorporated into recombinant proteins using a number of in vivo and
in vitro methods [1,2]. These non-natural insertions provide useful modifications that might take
place on the protein backbone or on the amino acids’ side chains. In nature, protein backbone
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modifications are the result of various post-translational modifications (PTMs), whereas in the frame of
reprogrammed protein translation, the easiest way to in vivo modification is to use proline analogs [3–6].
Other protein backbone modifications are typically produced using in vitro ribosomal translation
systems. For example, β-, or γ-amino acids can be inserted into target polypeptide sequences by
using engineered in vitro translation systems [1]. Notably, α-hydroxy acids can also be incorporated
into proteins, for example in response to in-frame amber codons via the action of specific engineered
systems [7]. However, the vast majority of ncAAs delivers modifications of protein side chains
with unique functionalities. A typical example in nature is the rare 22nd proteinogenic amino acid
pyrrolysine (Pyl), which appears in very few proteomes of methanogenic microorganisms [2].
Pyrrolysyl–tRNA synthetase (PylRS) is a particularly powerful enzyme that enables the
incorporation of various amino acid substrates into a protein. Its original natural substrate is the rare
proteinogenic amino acid pyrrolysine (Pyl), a lysine analog with a 4-methyl-pyrroline-5-carboxylate
ring attached to the lysine side chain [8–10]. It is recognized and enzymatically charged onto tRNAPyl,
forming a complex Pyl–tRNAPyl via the action of PylRS, which is a class II aminoacyl–tRNA synthetase
(aaRS) [11]. The anticodon of the cognate tRNA is CUA, providing a natural PylRS:tRNAPyl orthogonal
pair. This pair fulfils all requirements for a natural orthogonal translation system (OTS) capable of
in-frame stop codon suppression (SCS) and subsequent site-specific ribosomal incorporation of an
ncAA substrate into a recombinant target protein [12].
For a new ncAA to become amenable for genetic encoding, a specific aaRS variant is
required, whereas “polyspecific” variants recognize several substrates (e.g., 3-bromo-, 3-iodo-,
and 3-trifluoromethyl-l-phenylalanine) [13]. Commonly, the selection of molecular machineries capable
of ncAA incorporation is done via generation of gene libraries of a chosen aminoacyl-tRNA synthetase.
Two natural archaeal systems, the tyrosine pair of Methanocaldococcus jannaschii (MjTyrRS:tRNATyr)
and the pyrrolysine pair of the Methanosarcina species (PylRS:tRNAPyl) were rationally constructed
and used for the selection of new OTSs in Escherichia coli (E. coli) [14–17]. To date, these synthetase
scaffolds (MjTyrRS and PylRS) are predominantly used and enable site-specific incorporation of
diverse ncAAs into proteins in vivo. Orthogonal pairs (o-pairs) based on both the MjTyrRS and
Mm/MbPylRS scaffolds can have advantages and disadvantages in different experimental settings.
For each aaRS variant, it is crucial that cAAs are excluded from activation and thus not charged onto
the suppressor tRNA. In bacterial host cells, MjTyrRS often show a higher performance (e.g., yield of
purified ncAA-modified target protein) compared to PylRS-based systems. Commonly, orthogonal
translation with PylRS-derived o-pairs leads to low yields of target protein, since this enzyme generally
has a low catalytic efficiency. While o-pairs based on MjTyrRS are commonly efficient enough to allow
a higher number of in-frame stop codons that can be suppressed, this is not the case with orthogonal
translation based on PylRS.
The PylRS system particularly covers a wide range of applications for genetically encoding ncAAs
with bio-orthogonality in both prokaryotes and eukaryotes. Thus, tRNAPyl and PylRS represent a
so-called orthogonal pair for the corresponding host cells. Notably, the catalytic core containing
the ncAA substrate binding region is predominantly built of hydrophobic residues, where mutation
Y384F can increase the activity of PylRS [18]. The corresponding protein crystal structure showed that
the binding pocket was essentially unchanged, but the mutation enlarged the substrate range of the
enzyme [19]. The evolutionary origin and structural resemblance to PheRS explain why PylRS and
specific Y384 mutants exhibit better activity towards phenylalanine or tryptophan (as well as their
analogs) [20].
In this study, we combined the accumulated findings of various PylRS engineering and
improvement reports in order to expand the scope of MmPylRS toward novel aromatic ncAA analogs
(Figure 1) amenable to be used in both prokaryotic and eukaryotic hosts. These moieties are often
valuable probes for studying non-covalent interactions, hydrophobicity, and polarity effects in protein
structure, folding and activity. We constructed randomly and rationally designed MmPylRS gene
libraries to explore the diversity of ncAA incorporation [21,22]. Site-saturation mutagenesis (SSM)
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via NNK codons (N: A/T/C/G; K:G/T) was used to specifically randomize chosen positions of the
aaRS [23]. Our strategy is further based on an analysis of the available high-resolution molecular
structure of MmPylRS, as well as earlier reports showing that mutagenesis of the crucial positions
N346 and C348 (Figure 2) is feasible to expand the substrate range of this enzyme [24,25]. We make a
step further and include other residues in our mutagenesis schemes, importantly including second and
higher shell residues, which are expected to be important for ncAA substrate binding and recognition,
but not in direct contact. Our approach proves to be successful as we were able to design novel
enzyme variants that specifically recognize a set of aromatic analogs. In particular, a much higher
ribosomal incorporation efficiency can be achieved for 3-benzothienyl-l-alanine (Bta) relative to a
previous study [26].
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Figure 1. Chemical structure of Trp and Tyr analogs used in this study. 3-benzothienyl-l-alanine
(Bta), 3-(1-naphthyl)-l-alanine (1-NaA), β-(1-azulenyl)-l-alanine (AzAla), 4-benzoyl-l-phenylalanine
(Bpa), 1-methyl-l-tryptophan (1-MeW), 3-(2-naphthyl)-l-alanine (2-NaA), 3-chloro-l-tyrosine (3-ClY),
3-bromo-l-tyrosine (3-BrY), 3-iodo-l-tyrosine (3-IodY), and 3-methyl-l-tyrosine (3-MeY).
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Figure 2. Key residues surrounding the active site pocket of MmPylRS for amino acid substrate
recognition (PDB: 2Q7H [10]). The distance between N346 and the bound Pyl–AMP as indicated (red
dashed line) is 2.7 Å.
Joining current efforts, our main goal is to evolve MmPylRS variants dedicated to various tyrosine
and tryptophan analogs that have so far only been incorporated into proteins by MjTyrRS [16].
We succeeded to integrate 10 different aromatic analogs into this OTS using semi-rationally engineered
MmPylRS variants.
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2. Results
2.1. Engineering MmPylRS Variants for Aromatic Non-Canonical Amino Acids
2.1.1. MmPylRS Mutagenesis Strategy and Screening towards Tryptophan and Tyrosine Analogs
Initial MmPylRS gene libraries were constructed by mutating two key aaRS positions: N346
and C348 (Figure 2). Rational aaRS design aimed to provide specific enzyme–substrate interactions
that enable binding and activation of the corresponding ncAAs. Accordingly, active site residue
N346 was mutated to A, G, and S, whereas C348 was mutated to Q, N, and M. In previous studies,
the structures of two PylRS variants (N346G/C348Q and N346S/C348Q) were modeled, which revealed
crucial interactions between these aaRS side chains and substrates in the form of aromatic amino
acids [18,24,25,27,28]. Due to the increased bulkiness of the ncAA analogs, enlarging the enzyme
binding pocket may improve the access and recognition of the aromatic moieties, allowing charging
onto tRNAPyl and ribosomal incorporation. Next, based on the PylRS structure and activity data
collected from a large number of enzyme mutants, residues V401 and W417 (Figure 2) were targeted.
These were expected to define ncAA specificity towards hydrophobic or polar amino acids [10,29].
Moreover, positions L305, Y306, and L309 shape the aaRS active site pocket. These five positions (L305,
Y306, L309, V401, and W417) were chosen for full randomization as they have direct influence on
enzyme activity (Figure 2). The PylRS Y384F mutation, which conferred an increased aminoacylation
rate in previous studies, was introduced into the starting PylRS sequence and remained fixed in all
mutants [18,20]. Novel and semi-rationally designed MmPylRS gene libraries capable of activating
aromatic ncAAs were successfully constructed. To detect the ribosomal incorporation of the chosen
Trp and Tyr analogs, a reporter construct of super–folder green fluorescent protein (sfGFP) was
used. The sfGFP gene contained an in-frame amber stop codon at the position downstream of the
first methionine encoding codon (sfGFP–R2TAG) and a C-terminal His-tag. In this way, the sfGFP
fluorescence signal of intact cells can be used as readout for the in vivo suppression of the in-frame
amber stop codon, with fluorescence intensity and full-length protein yields proportional to suppression
efficiency [23].
Next, a set of aromatic ncAAs were selected for testing (Figure 1). These substrates were supplied
to E. coli BL21(DE3) cell cultures co-expressing the genes of designed MmPylRS variants with cognate
tRNAPyl and the sfGFP–R2TAG reporter. We utilized 96-well plate setups with MmPylRS variants and
ncAAs screening protocols similar to those established by the Söll lab to analyze changes in the aaRS
efficiency and substrate specificity [13,20,30]. Cells were grown in 96-well plates filled with chemically
defined medium separately supplemented with all 20 cAAs, which leads to an observable fluorescence
background, and individual target ncAAs (Tables S2 and S3). Owing to the established reporter
methodology, the efficiency of ncAA charging onto the amber suppressor tRNAPyl in vivo is directly
correlated with the intensity of the fluorescence signal. Similar to recent reports, these screenings
revealed fluorescence of sfGFP upon incorporation of aromatic Tyr or Trp analogs mediated by the
individual MmPylRS variants [31,32]. Herein, the different enzyme variants are named according to the
introduced mutations, e.g., MmPylRS–SMG corresponds to the aaRS mutation set N346S/C348M/V401G.
Mutations in the individual enzyme variants are listed in Supplementary Table S1. Activity screenings
revealed fluorescence signals significantly above background with MmPylRS–SMG in the presence
of Bta and 1-NaA (Figure 3A), whereas MmPylRS–GML (mutation set N346G/C348M/W417L) was
capable of activating 3-ClY and 3-BrY (Figure 3B). These results demonstrated that the MmPylRS
variants with V401 mutations were amenable to Trp analogs, while aaRS variants containing W417
mutations were capable of Tyr analog activation and tRNA charging (Figures S1 and S2).
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Figure 3. In vivo a ber suppression capacities and analytics of ncAA incorporation at a ber sites
ith t o different mPylRS variants: (A) mPylRS–S G and (B) mPylRS–G L. The library for
nc incorporation was screened by monitoring sfGFP–R2TAG reporter fluorescence intensity. Details
of the library screening with MmPylRS variants and ncAAs in 96-well plates are given in Table S2 and
S3. Each amino acid was supplied at a final concentration of 1 mM. (Control: no inducer and no ncAAs;
no nc s: with inducer but without amino acids supplementation). Data in (B) is means ± SD (n = 3).
2.1.2. Intact Protein Mass Analysis of Aromatic ncAA Incorporation
To validate the results from the screening assays, protein mass spectra were acquired.
NcAA-modified sfGFP reporter protein variants were produced in bacterial cells via the action of the
MmPylRS variants, purified and analyzed in electrospray LC–MS (Q–TOF, quadrupole time-of-flight
mass spectrometry). Intentionally, standard T7 expression E. coli cells were used, but we want to remark
that so histicated strains for improved amber suppression have been developed [33]. The presence of
aromatic ncAAs generates characteristic mass shifts in the intact protein mass spectra. As expected from
revious results shown in Fi ure 3, the Trp derivatives Bta and 1-NaA were successfully incorporated
by co-expression of MmPylRS–SMG, while MmPylRS–GML mediates efficient incorporation of the Tyr
derivatives 3-ClY, 3-BrY, and furthermore 3-IodY (Figure 4). In this way, the mass analysis corroborates
the small-scale fluorescence assay results.
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2.2. Improvement of Amber Suppression Efficiency
2.2.1. Bta Incorporation Efficiency Compared to Other MmPylRS Variants
Al hough the results showed the MmPylRS variants successfully activating aromatic ncAAs,
the efficiency of PylRS-based stop codon suppression in bacterial cells remained relatively low. This can
be seen from weak fluorescence signals from the reporter proteins containing ncAAs, as reported
in [13,34]. Considering the poor enzyme kinetics of many engineered PylRS systems, we chose to
further optimize the enzyme variants. Bta is a close structural analog of Trp, and it was incorporated
by the MmPylRS variant dubbed BtaRS carrying the two active site mutations N346G and C348Q [26].
We carried out a site-directed mutagenesis towards an improved Bta incorporation and found that
mutation of position V401 to glycine led to a multifold improvement in Bta incorporation efficiency
(Figure S3). Several other strategies to achieve better ncAA incorporation have recently been developed.
For example, the archaeal MmPylRS gene can be codon-optimized to enhance the recombinant
synthetase gene expression and its overall efficiency within the bacterial host cell. As reported earlier
for MbPylRS, this can increase the intracellular amount of soluble and functional synthetase, which in
turn increases full-length target protein yields [35]. When compared with the natural archaeal gene
sequence as used in previous works, the codon-optimized MmPylRS gene led to an increased ribosomal
Bta incorporation efficiency (Figure S4)
2.2.2. Enhancing the Efficiency of Ribosomal Bta Incorporation and Target Protein Yields
Previous studies have documented aaRS mutations, especially in the N-terminal portion of PylRS,
which led to improved synthetase activity. Moreover, a chimeric pyrrolysyl–tRNA synthetase variant
(chPylRS, comprising the N-terminal aaRS part of MbPylRS and the C-terminal part of MmPylRS)
was reported to benefit from the mutations V31I, T56P, H62Y, and A100E (IPYE), which were found
by continuous directed evolution [34]. We compiled previously found positions in PylRS that can
be beneficial for aaRS activity in the recombinant setting. The resulting set of sites (T13, V31, I36,
T56, R61, H62, H63, A100, and S193) was chosen for mutagenesis studies to further improve Bta
incorporation, monitored as before using the sfGFP reporter (Figure S5) [36,37]. From this dataset of
rational PylRS mutagenesis and activity screening, it became apparent that considerable improvements
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arise upon mutation of aaRS position S193. Thus, we chose to pursue a full site saturation mutagenesis,
generating and testing all 19 possible enzyme variants (Figure S6). For the efficiency of Bta incorporation,
replacement of S193 by positively charged (Lys, Arg, and His), amidic (Asn and Gln), or small side chain
(Ala and Gly) amino acids proved beneficial. However, when S193 was replaced with negatively charged
(Asp and Glu) or aromatic (Phe, Tyr, and Trp) amino acids, the efficiency of stop codon suppression
dropped (Figure S6). The aaRS protein structure solved in previous studies (see Appendix A) indicates
that position S193 is located in the C-terminal domain of MmPylRS but spatially close to the N-terminal
domain, and is thus associated with tRNA charging activity [36,38,39]. Based on the activity profiles,
PylRS variant SMG was combined with the mutation sets IV (T13I and I36V) [37], IPYE (V31I, T56P,
H62Y, and A100E) [34], and KYR (R61K, H63Y, and S193R) [36,40], respectively, to improve ribosomal
Bta incorporation in vivo (Figure 5A). As a result, MmPylRS–KYR_SMG, which includes the potent
S193R mutation, led to higher sfGFP reporter fluorescence.
Therefore, we propose that mutations of S193 (especially to positively charged residues) provide a
good strategy to enhance the ncAA incorporation efficiency of the PylRS system. For the obtained
data sets, we chose to continue creating additional PylRS mutation sets and combinations thereof.
Notably, the MmPylRS–13IPYER_SMG variant (containing mutations T13I, T56P, H62Y, A100E, S193R,
N346S, C348M, and V401G) yielded the highest Bta-dependent reporter fluorescence intensity
(Figure 5B). At the same time, the background of stop codon suppression (reporter signal in the
absence of Bta supplementation) is not increased. This indicates that the efficiency and specificity
of MmPylRS–13IPYER_SMG in vivo are greatly enhanced by introducing these combined mutations,
yielding more ncAA-modified target protein for the same amount of ncAA supplied.
Target protein production and purification were performed to further validate the increased Bta
incorporation efficiency by the newly generated MmPylRS variants. As in previous works, we fused the
sfGFP (R2TAG) reporter with a His- and a small ubiquitin-like modifier (SUMO) tag at the N-terminus
to enable detection and purification of the truncation product generated by translation termination
at the amber position [23]. Protein production was performed in the presence of Bta and MmPylRS
variant co-expression. In this setup, aaRS variants enabling high Bta incorporation efficiencies should
predominantly lead to the production of full-length target protein, whereas those with poor efficiency
should result in lower amounts of full-length protein and increased amounts of truncation product.
Four MmPylRS constructs were chosen for evaluation, namely MmPylRS–SMG, codon-optimized
MmPylRS–coSMG, MmPylRS–KYR_SMG, and MmPylRS–13IPYER_SMG. The target proteins were
purified through the N-terminal His-tag and yields were quantified. Remarkably, MmPylRS constructs
with the S193R mutation (MmPylRS–KYR_SMG and MmPylRS–13IPYER_SMG) ribosomally expressed
mostly full-length fusion protein with only few truncation products, as evidenced by SDS–PAGE
(Figure S8). Obtained protein yields were calculated per liter of bacterial culture in M9 minimal
medium and measured by absorbance at 488 nm, which originates from the sfGFP chromophore.
Yields of full-length SUMO–sfGFP were 6 mg for MmPylRS–SMG, 11 mg for MmPylRS–coSMG, 12 mg
for MmPylRS–KYR_SMG, and 14 mg for MmPylRS–13IPYER_SMG, nicely demonstrating the effect of
the efficiency-improving secondary aaRS mutations.
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2.3. Improvement of Enzyme Efficiency Toward Other ncAAs
Bta incorporation efficiency was strongly increased through our combined MmPylRS engineering
strategies. Next, we set out from our semi-rationally designed aaRS scaffold to test if more and novel
ncAAs can be activated. Indeed, some new ncAAs were incorporated into the sfGFP reporter
upon co-expression of the improved MmPylRS variants. Albeit with relatively low efficiency,
β-(1-azulenyl)-l-alanine (AzAla) was incorporated in case of the MmPylRS–SMG mutants with
the mutation sets KYR and W417 amino acid substitutions (W417L, W417K, or W417I). Moreover,
4-benzoyl-l-phenylalanine (Bpa) was incorporated by MmPylRS–SMI (N346S, C348M, and W417I)
and MmPylRS–SML (N346S, C348M, and W417L) variants bearing the KYR modification (Figure 6B).
To validate the fidelity of ncAA incorporation, the purified target proteins were analyzed by ESI-MS.
The results were consistent with the data from fluorescence screening and showed that both AzAla
and Bpa were successfully incorporated into the target protein (Figure S9). Moreover, mass spectra of
the intact proteins revealed successful installation of the ncAAs 1-MeW (MmPylRS–KYR_SMG) and
3-MeY (MmPylRS–KYR_SMGI) (Figure S9).
2.4. Evaluation of Amber Suppression Efficiency and Other Growth Media
To further evaluate the efficiency of the created PylRS variants, wild-type sfGFP (wt–sfGFP)
without an in-frame amber stop codon was included in reporter assays. Based on previous fluorescence
screens, highly active aaRS constructs were selected for analysis. As seen before, the site-specific
incorporation of Bta into the target protein is most efficient when mediated by MmPylRS–KYR_SMG
(Figure S10). Comparing the fluorescence intensities, this OTS reaches a suppression efficiency of 50%
relative to the wt–sfGFP control under identical conditions. For an OTS based on PylRS, this represents
high activity and target protein production [34]. Moreover, further controls were included at this stage.
When only tRNAPyl (but no PylRS enzyme) was co-expressed, slightly elevated but still negligible
background levels of amber suppression were observed. Under identical conditions, these were not
elevated when the aaRS was also co-expressed but no ncAA supplied (Figure S10).
As often conducted for PylRS-based systems, our OTS activity screening and characterization were
performed in chemically defined minimal media [28,41]. In order to test the robustness and versatility
of the ncAA incorporation systems, target protein production was performed in a chemically-defined
auto-induction medium developed for ncAA incorporation [42] and further in commonly used complex
rich media. As above, wt–sfGFP was included as reference for recombinant protein production
in the absence of amber suppression. Again, orthogonal translation with MmPylRS–KYR_SMG
displayed the highest Bta incorporation efficiency, reaching maximum yields when conducted in
LB medium (Figure S11). Successful ncAA incorporation into the target protein was validated via
ESI-MS (Figure S12). Commonly used for recombinant protein production (for example for protein
crystallography), TB medium also proved suitable for the two top performing systems based on
MmPylRS–KYR_SMG and MmPylRS–13IPYER_SMG, respectively.
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3. Discussion
Nowadays, numerous ncAAs can be site-specifically incorporated into proteins of interest
by expanding the genetic code. One of the major applications of OTSs is the possibility to
mimic post-translational modifications (PTMs) in a precisely controlled manner [43]. In contrast,
other traditional methods of protein modifications usually lead to non-specific labeling, yielding a
heterogeneous and complex protein mixture [44]. Indeed, the microheterogeneity of proteins upon
labelling is an important issue when attempting specific PTMs with desired chemical modifications,
both natural and non-natural. Consequently, selective methods that allow absolute control of the
position of the reactive handle within a protein are required [45].
Despite the widespread use of various PylRS:tRNAPyl pairs in orthogonal translation, the substrate
range of the engineered aaRS variants, stemming from its natural one, is mostly restricted to lysine
analogs with long, flexible side chains [10]. It is desirable to expand the substrate range of these
systems towards amino acids with aromatic side chain derivatives such as Trp. For example, in many
protein–protein interactions, Trp residues are essential [46,47]. However, their role is difficult to
investigate via spectroscopy because their absorption and fluorescence signals are more or less
indistinguishable from other non-essential Trp residues present in the protein [48]. In this context,
Trp-like ncAAs are distinct chromophores offering unique advantages of intrinsic probes, especially in
complex biological settings such as mammalian cells, tissues, and even whole animals. Furthermore,
such ncAAs are likely a good tool for investigating protein–protein or protein–nucleic acid interactions
due to their unique spectroscopic signature [49].
For installation of such moieties, widely used orthogonal MmPylRS variants designed by
evolutionarily or rationally based methods fit perfectly into this scheme. However, the low ncAA
incorporation efficiency of PylRS in bacterial systems limits its utility for OTS development [34]. This is
often mitigated by supplying higher amounts of chemically synthesized ncAA to the bacterial growth
medium. For that reason, we present here a potentially useful approach to expand the substrate range
and activity of MmPylRS towards Trp and Tyr analogs, employing an enhanced ncAA set in microtiter
plate screening, which quickly identifies novel substrates enabled by rational or random mutagenesis.
Our approach has the following advantages over previously reported systems: (i) PylRS is compatible
with both eukaryotic and bacterial expression systems, (ii) it enables the translation of spectroscopically
valuable aromatic ncAAs (such as AzAla) and (iii) significantly improves the target protein yields of
related OTSs for the same amount of ncAA supplied to the host cells.
In our study, mutations at positions V401 and W417 of MmPylRS are expected to reshape the
aaRS binding pocket, allowing the synthetase to activate the bulkier Trp and Tyr analogs. Based on
the structures of wild-type and a mutant MmPylRS, the binding pocket of the aaRS includes four
critical residues (N346, C348, V401, and W417) [26]. Rational mutagenesis of these residues to smaller
side chains might enlarge the binding pocket to accommodate larger ncAA substrates (Figure 2).
In particular, N346 and C348 were suggested to act like substrate gating residues in earlier studies and
their rational manipulation would make it possible to expand the substrate repertoire of MmPylRS.
The Bta-dedicated engineered enzyme BtaRS created by double mutations (N346G/C348Q) clearly
supports this notion [26]. We engineered an alternative OTS with higher efficiency of Bta incorporation
by mutation set N346S/C348M/V401G. This shows that based on the same aaRS scaffold, there can be
multiple solutions to recognize and activate a given ncAA substrate. From the aaRS mutagenesis and
screening results, it is evident that the subtle interactions between ncAA substrate and the enzyme can
benefit from multiple mutations, which establish and fine-tune selectivity and activity.
Following the same strategy, aaRS variant MmPylRS–GML was constructed, which efficiently
activates halogen-modified Tyr analogs, leading to their site-specific ribosomal incorporation.
Upon introduction of a second halogen moiety (e.g., 3,5-diClY and 3,5-diBrY), however, ncAA
incorporation signals drop, which may indicate that, once again, the size and shape of the aaRS active
site hits limits for the accommodation of more bulky ncAA substrates.
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Previous studies reported that besides residues in the vicinity of the active site pocket,
also N-terminal mutations within the PylRS sequence or can improve the efficiency of ncAA
incorporation [34]. For instance, for the relatively weak starting level of AzAla incorporation,
the impact of the activity-enhancing mutation set becomes evident. In this context, it is particularly
important to note that the mutation of MmPylRS residue S193 proved to enhance the Bta incorporation
efficiency. This residue is located at the C-terminal domain of the aaRS and takes part in tRNA
binding [40]. Thus, mutations of S193 may be beneficial due to the alteration of interaction between
the synthetase and tRNA, and not the actual activation of the amino acid substrate. Consequently,
S193 mutagenesis results may be transferrable to several previously developed PylRS-based systems.
Site-specifically installed, the use of Trp analogs is not only an interesting approach to modify
protein spectral properties. Such analogs are also excellent tools for biophysical studies of proteins as
non-invasive probes, capable of minimizing potential structural perturbation of the protein scaffold.
A subtle exchange on aromatic side chains (e.g., -H->F, or -CH3), also known as “atomic mutations”,
are especially useful for performing various fine-tuned biophysical studies [50,51]. For example, both
Bta with its sulfur heteroatom and AzAla with its unique blue fluorescence emission and vibrational
properties are interesting biophysical probes (e.g., exhibit a large dipole moment, a narrow energy
gap between the HOMO and LUMO, and abnormal fluorescence) [52–54]. They would allow for
observing the electronic vibration and transfer, which are particularly relevant to all aspects of protein
structure, activity, and functions with charge stabilization [55]. In addition, both ncAAs are interesting
biomedical agents and bioactive peptide building blocks [56–58].
Finally, MmPylRS-based systems for Trp analogs have great potential in various omics setups.
For example, Sakamoto and co-workers used several engineered PylRS variants for a proteome-wide
reassignment of rare-sense codons with ncAA analogs [36]. Such studies could also be widened to
cellular proteins and enzymes that bind DNA, such as molecular switches, restriction and repair
enzymes, gyrases or nucleosomal and nucleic acids-associated proteins. It should not be difficult
to imagine how repressor or activator proteins equipped with suitable Trp analogs can either block
the access of enzymes such as polymerases to DNA or enhance their binding to DNA—opening up
completely new avenues in investigating complex biological phenomena and processes [59].
4. Materials and Methods
4.1. Canonical and Non-Canonical Amino Acids
A total of 20 canonical amino acids were purchased from Sigma. Non-canonical amino acids were
from Bachem, abcr GmbH, Alfa Aesar, Merck, Biosynth, TCI, and Abchem (see Table S3).
4.2. Site-Directed Mutagenesis, Strains, and Screening Library Construction
MmPylRS gene engineering was conducted via PCR using mutagenic primers with NNK (N = A,
T, G, or C; K = G or T) randomizations at designated positions (S193, V401, and W417). Primers were
synthesized by Merck, Darmstadt, Germany [28,60]. Primer sequences are listed in the Supplementary
Materials (Note S2). The pBU16 plasmid containing pyrrolysyl–tRNACUA driven by glnS’ promoter
was digested with NdeI and KpnI [60]. The digested PCR products and linearized plasmid were
ligated using T4 DNA ligase, and transformed into E. coli strain Top10. The gene of sfGFP containing
an in-frame amber codon (sfGFP–R2TAG) used as a reporter for amber suppression was cloned into
plasmid vector pET-28. For intact cell fluorescence experiments, an N-terminal His-tag fused with
SUMO–sfGFP based on reporter constructs carrying an in-frame amber codon at position R2 was
cloned in pET-28, as reported earlier [23].
4.3. Screening aaRS Variants for Activity
To screen the MmPylRS variants for activity towards Trp and Tyr analogs, the two plasmids,
pBU16–MmPylRS–tRNAPylCUA and pET-28–sfGFP_R2TAG, were co-transformed into E. coli strain
Molecules 2020, 25, 4418 13 of 18
BL21(DE3) [60]. Single colonies were chosen from the plate and pre-cultured in 1 mL of LB medium
supplemented with Amp (100 µg/mL) and Kan (100 µg/mL) at 37 ◦C overnight. Then, the pre-cultured
cells were transferred (ratio 1:500) to 20 mL fresh LB medium and incubated at 37 ◦C. When the
optical density (OD600) of the cultures reached 0.50–0.8, cells were centrifuged and resuspended
twice in M9 minimal medium (M9 salts (7.52 g/L Na2HPO4·2H2O, 3 g/L KH2PO4, 0.5 g/L NaCl,
and 0.5 g/L NH4Cl), 0.4% glucose, 1 mM MgSO4, 1 mg/mL thiamine, 1 mg/mL biotin, and 0.3 mM
CaCl2). The cells were cultured in M9 minimal medium (with 100 µg/mL Amp, 100 µg/mL Kan, and
1 mM isopropyl-β-D-thiogalactoside (IPTG)) and distributed (200 µL) in a 96-well black µ-plate (Ibidi,
Martinsried, Germany) containing different ncAAs at a final concentration of 1 mM in each well.
The plates were incubated at 37 ◦C with shaking for 18 h. Fluorescence intensities and OD600 were
monitored by an Infinite M200 microtiter plate reader (Tecan, Männedorf, Switzerland), the former
via bottom reading (excitation wavelength of 481 nm, emission wavelength of 511 nm, and a manual
gain of 85) every 10 min. The screening library system contains four wells for the background signals
(control), 20 cAAs, and 50 ncAAs (full details of arrangement are in Table S2).
4.4. Protein Production and Purification
To produce sfGFP with site-specific ncAA incorporation, plasmid vectors pBU16–MmPylRS–
tRNAPylCUA and pET-28–sfGFP_R2TAG were co-transformed into E. coli strain BL21(DE3). Single colonies
were picked and pre-cultured in 1 mL of LB medium supplemented with Amp (100 µg/mL) and
Kan (100 µg/mL) at 37 ◦C overnight. After cultivation, cells were harvested by centrifugation and
resuspended in M9 minimal medium. In a ratio of 1:500, the pre-culture was transferred into 100 mL
M9 minimal medium supplemented with Amp and Kan and grown at 37 ◦C until OD600 reached 0.6–0.8.
Target gene expression was induced by the supplementation of 1 mM IPTG and ncAAs followed by
incubation at 37 ◦C for 18 h. The cells were harvested and resuspended in phosphate buffered saline
buffer (PBS buffer, pH 7.5). Lysozyme (0.5 mg/mL), DNase (10 µg/mL), and RNase (10 µg/mL) were
added and the cells incubated at 4 ◦C for 30 min. Cells were further lysed via sonication (Sonopuls
HD3200, Thermo Fisher Scientific, Germany) for 10 min (45% amplitude, 2 s pulse, 3 s pause). After
centrifugation (45 min, 12,000 rcf, 4 ◦C), the supernatant was separated from the pellet. The supernatant
was applied onto 1 mL Ni–NTA columns (GE Healthcare, München, Germany) for protein purification.
First, 10 mL PBS buffer was used to wash the column. After supernatant application, non-target
proteins were washed out by 10 mL washing buffer (1X PBS buffer, 20 mM imidazole, pH 7.4). Target
proteins were eluted from the resin by 5 mL elution buffer (1X PBS buffer, 300 mM imidazole, pH 7.4).
After purification, the buffer was exchanged to storage buffer (1X PBS buffer, pH 7.4) by dialysis.
4.5. Mass Spectrometry
To determine if MmPylRS mutants mediate ncAA incorporation into sfGFP, intact protein masses
were confirmed by electrospray ionization mass spectrometry (ESI-MS). After infusing the proteins
through a C5 column (Supelco analytical, Sigma-Aldrich) by an Agilent 1260 HPLC system, ions
were analyzed by an Agilent 6530 Q-TOF instrument. Spectra deconvolution was performed using
Agilent Mass Hunter Qualitative Analysis software (v. B.06.00) employing the maximum entropy
deconvolution algorithm. Observed protein masses were compared to theoretical values.
5. Conclusions
The class II aminoacyl–tRNA synthetase enzyme PylRS is structurally similar and belongs to
the same evolutionary group as the bacterial phenylalanyl–tRNA synthetase (PheRS). Therefore, the
change in substrate specificity of PylRS towards aromatic canonical and non-canonical amino acids
by rational manipulation and library design is plausible. For example, the common evolutionary
origin also explains why the Y384F mutants of PylRS can have better activity towards phenylalanine or
tryptophan (and their analogs) [41,61,62].
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In this study, we engineered the MmPylRS synthetase towards the incorporation of several
aromatic ncAA substrates. Over multiple stages, we selected positions in the enzyme for mutagenesis
and used a fluorescence-based assay to screen for aaRS activity in vivo. Seven positions (L305, Y306,
L309, N346, C348, V401, and W417) were chosen from the active site pocket of the aaRS. We found
that modification of MmPylRS at residue V401 significantly improved the enzyme performance with
the sulfur-containing aromatic ncAA Bta. In addition, residue W417 expanded the substrate range
of the enzyme towards Tyr analogs. The interest in site-specifically installed ncAAs has fueled
continuous efforts to create and optimize OTSs. Even for the commonly catalytically superior MjTyrRS
systems, enzyme and host strain engineering efforts continue to improve target production and amber
suppression background [63]. For PylRS, the accumulated literature allowed us to test if previously
reported mutations also act on the Bta-specific enzyme created herein. Compiled from previous works,
we selected several spatially distant positions (T13, V31, I36, T56, R61, H62, H63, A100, and S193),
which are not directly involved in the binding pocket of the aaRS, for site-directed mutagenesis studies
to improve efficiency. Interestingly, we found that synthetase performance in vivo benefits from
mutation of residue S193, which is located in the C-terminal domain suggested to interact with tRNAPyl.
Therefore, our approach not only expands the MmPylRS substrate range but also significantly improves
the efficiency of the enzyme variants. Specifically, the incorporation of the well-known translationally
active ncAA Bta proved to be enhanced. In addition, we successfully incorporated AzAla and 3-MeY
site-specifically into proteins using a MmPylRS–based OTSs for the first time. Again, this seems to be
possible due to the enhanced activity of the orthogonal pair in E. coli.
Finally, we envision our approach as a strategy for overcoming the problems with the low
efficiency of aaRS variants as a route to the discovery of new orthogonal enzymes. It focuses on the
combined mutagenesis of first-shell and spatially distant residues, the latter for example belonging to
the tRNA binding domain [34,36,37]. In this light, combination with computational approaches should
lead to aaRS variants with specificities towards synthetic substrates and activity levels comparable to
the wild-type aaRS [63]. This will significantly expand the chemical space and scope of orthogonal
translation with numerous aromatic ncAAs useful in biophysics, cell and synthetic biology [53,64].
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Figure A1. Crystal structure of wild-type MmPylRS and MmPylRS–tRNAPyl complex (PDB ID 2Q7H 
and 5UD5). (A) Molecular microenvironment of residue S193 located outside of the active site pocket 
but in the C-terminal tRNA binding domain. (B) Additional aaRS residues T13, V31, I36, T56, R61, 
H62, and H63 located in the MmPylRS N-terminal domain and important for activity in vivo. 
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